Trials / Completed
CompletedNCT00783081
Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 387 (actual)
- Sponsor
- Kowa Research Institute, Inc. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of K-134 for the treatment of intermittent claudication.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | K-134 | K-134 is given as low dose mid dose and high dose tablets for 26 Weeks. |
| DRUG | Cilostazol 100 mg BID | Cilostazol 100mg BID for 26 weeks. |
| DRUG | Placebo | Placebo BID for 26 weeks. |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2008-10-31
- Last updated
- 2012-03-22
Locations
42 sites across 2 countries: United States, Russia
Source: ClinicalTrials.gov record NCT00783081. Inclusion in this directory is not an endorsement.